Idiopathic cystitis in cats: does pentosan polysulfate reduce the frequency and severity of urinary signs? — POSSIBLE (the treatment made no difference)

In cats with idiopathic cystitis, does pentosan polysulfate vs placebo reduce frequency and severity of urinary signs?

Shelf #712 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE (the treatment made no difference): Both randomised, double-blind, placebo-controlled trials of pentosan polysulfate in feline idiopathic cystitis were null on their clinical outcomes. Wallius & Tidholm 2009 (18 cats with idiopathic, non-obstructive lower urinary tract disease; subcutaneous pentosan polysulfate 3 mg/kg on days 1, 2, 5 and 10 vs placebo, re-evaluated out to 12 months): no statistically significant differences concerning clinical signs between groups during treatment or at any re-evaluation; 6 of 18 cats (33%) showed recurrence of clinical signs during the entire study period, and at 6 and 12 months all remaining 16 cats were healthy — the disease was self-limiting without treatment. Delille 2016 (35 cats with obstructive feline idiopathic cystitis; intravesical pentosan polysulfate 30 mg vs saline at catheter placement and after 24 and 48 hours): recurrent urethral obstruction occurred in 3 of 18 pentosan cats and 3 of 17 placebo cats (P=1.000) — 16.7% versus 17.6% — and there was no difference in the clinical score between groups. Design class (a): randomisation and blinding are established by both carded records (each describes itself as randomised, placebo-controlled and double-blind/blinded, and both carry MeSH Double-Blind Method). The honest limits: both trials are small (18 and 35 cats), so a modest benefit confined to a subpopulation — for example cats with continuous or frequently recurring signs, the group Wallius & Tidholm propose for future trials — is not excluded; and the two trials differ from each other in route (subcutaneous vs intravesical) and population (non-obstructive vs obstructive), and neither tests oral administration. Drafted Nov 10, 2026 (VetMed build, topic #712); all figures from records fetched and verified at drafting.

Wallius & Tidholm 2009: subcutaneous pentosan did not differ from placebo on clinical signs at any point over 12 months in 18 cats with idiopathic, non-obstructive lower urinary tract disease (the treatment made no difference)

Double-blind, randomised, placebo-controlled trial (record's own wording in its title and abstract; publication type: Randomized Controlled Trial; MeSH includes Double-Blind Method)

Who: Cats: 18 cats with idiopathic, non-obstructive feline lower urinary tract disease; 9 were treated with pentosan polysulphate and 9 with placebo, by subcutaneous injection of 3 mg/kg pentosan polysulphate or placebo on days 1, 2, 5 and 10. The study was double-blind, randomised and placebo-controlled. Re-evaluation was performed after 5 and 10 days, 2 weeks, and 2, 6 and 12 months.

Result: There were no statistically significant differences concerning clinical signs between groups during treatment or at re-evaluation. Six cats (33%) showed recurrence of clinical signs during the entire study period, and only one of these cats had more than one recurrent episode. One cat (placebo) was euthanased 7 days after initial treatment because of recurrence of clinical signs, and another cat (placebo) was euthanased for other reasons after 6 months. At 2 weeks, two cats (one placebo, one pentosan) showed clinical signs; at the 2-month re-evaluation one cat showed mild clinical signs; at 6 and 12 months all remaining 16 cats were healthy. The authors conclude that idiopathic, non-obstructive feline lower urinary tract disease is a self-limiting disease with good short-term and excellent long-term prognosis without treatment, and that whether pentosan may benefit a subpopulation with continuous or frequently recurring signs remains for future trials of that subpopulation.

Watch out: Very small (9 cats per group), and the one reported baseline imbalance ran against pentosan: pentosan-treated cats had experienced significantly more pretreatment stressful events than placebo cats. Recurrence is reported for the whole study population (6 of 18), not per group, so no per-arm recurrence rate can be stated from this record. The two euthanasias were both in the placebo group but are reported as events, not as a treatment-effect finding, and no mortality benefit is claimed on this shelf.

Wallius BM, Tidholm AE. Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: a double-blind, randomised, placebo-controlled trial. J Feline Med Surg. 2009;11(6):409-12. PMID: 18996037. Registry ID: none in the record. MeSH: Animals · Cat Diseases/drug therapy* · Cats · Dose-Response Relationship, Drug · Double-Blind Method · Pentosan Sulfuric Polyester/therapeutic use* · Severity of Illness Index · Treatment Outcome · Urologic Diseases/drug therapy, veterinary*

Delille 2016: intravesical pentosan did not change recurrent urethral obstruction (3/18 vs 3/17, P=1.000) or clinical scores in 35 cats with obstructive idiopathic cystitis (the treatment made no difference)

Randomised, placebo-controlled, blinded clinical study (record's own wording; publication type: Randomized Controlled Trial; MeSH includes Double-Blind Method)

Who: Cats: 35 cats with obstructive feline idiopathic cystitis (male cats, per the record's MeSH). On day 0, cats were randomised to receive either 30 mg pentosan polysulfate sodium in saline (18 cats) or saline alone as placebo (17 cats), instilled intravesically at the time of indwelling urinary catheter placement and repeated after 24 and 48 hours; the catheter was clamped for 30 minutes after each administration before connection to a sterile urine collection system, and was removed after the third administration. Treatment success was assessed via the incidence of recurrent urethral obstruction, a scoring system for physical examination and daily urinalysis from day 0 to 5.

Result: Recurrent urethral obstruction occurred in 3 of 18 cats in the pentosan group and 3 of 17 cats in the placebo group (P=1.000) — 16.7% versus 17.6%. There was no difference in the clinical score between the groups in the investigated time period. Haematuria measures moved in opposite directions by method: the pentosan group showed a significantly lower degree of microscopic haematuria between day 5 and day 0 (P≤0.05), while the placebo group showed a significantly lower degree of dipstick haematuria between day 5 and day 0 (P≤0.05). The authors conclude that intravesical instillation of pentosan polysulfate sodium three times within 48 hours at the chosen dose had no influence on the incidence of recurrent urethral obstruction and clinical signs in cats with obstructive feline idiopathic cystitis.

Watch out: This is the obstructive emergency population and an intravesical route — a different subpopulation and delivery from subcutaneous or oral pentosan for recurrent non-obstructive signs. It is carded because it is a second randomised, blinded, placebo-controlled test of the same drug in the same disease and it agrees with the direct trial; by itself it does not answer the chronic-signs question.

Delille M, Fröhlich L, Müller RS, Hartmann K, Dorsch R. Efficacy of intravesical pentosan polysulfate sodium in cats with obstructive feline idiopathic cystitis. J Feline Med Surg. 2016;18(6):492-500. PMID: 26116618. Registry ID: none in the record. MeSH: Administration, Intravesical · Animals · Cat Diseases/drug therapy* · Cats · Cystitis/drug therapy, veterinary* · Double-Blind Method · Glycosaminoglycans/administration & dosage, therapeutic use* · Male · Pentosan Sulfuric Polyester/administration & dosage, therapeutic use* · Physical Examination/veterinary · Treatment Outcome · Urethral Obstruction/drug therapy, veterinary* · Urinary Catheterization/veterinary

Synthesis: two randomised, double-blind, placebo-controlled trials found pentosan polysulfate made no difference to urinary signs in feline idiopathic cystitis — POSSIBLE (the treatment made no difference)

Synthesis

Who: Synthesis of the cards above: Wallius & Tidholm 2009 (18 cats with non-obstructive idiopathic lower urinary tract disease; subcutaneous pentosan polysulphate 3 mg/kg on days 1, 2, 5 and 10; 12-month follow-up) and Delille 2016 (35 cats with obstructive feline idiopathic cystitis; intravesical pentosan polysulfate sodium 30 mg three times within 48 hours).

Result: Synthesis: (1) In non-obstructive disease, clinical signs never differed between pentosan and placebo at any of the six re-evaluations over 12 months, and all 16 remaining cats were healthy at 6 and 12 months regardless of treatment allocation. (2) In obstructive disease, recurrent urethral obstruction was essentially identical (3 of 18 vs 3 of 17, P=1.000; 16.7% versus 17.6%) and clinical scores did not differ. (3) The natural history shown by the placebo arms — signs settling without treatment — is itself the key context for any uncontrolled claim of pentosan benefit. On the carded evidence, pentosan polysulfate has not been shown to reduce the frequency or severity of urinary signs in feline idiopathic cystitis.

Watch out: Both trials are small, so the stamp is POSSIBLE rather than stronger: a benefit confined to cats with continuous or frequently recurring signs remains untested in an adequately sized trial, as Wallius & Tidholm themselves propose, and neither carded trial tested oral administration. Pentosan polysulfate for osteoarthritis in dogs is a different species and disease, homed at Shelf #512; no records are shared between the two shelves.

Synthesis of Wallius BM et al. PMID: 18996037; Delille M et al. PMID: 26116618. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.